Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744869 | 0.82 | KDM4E (0.40) | EGLN2ALDH1A1MAPK1KDM4ETSHR | |
| SCHEMBL3426730 | 0.82 | MAPK1 (0.36) | EGLN2ALDH1A1MAPK1KDM4ETSHR | |
| SCHEMBL14270922 | 0.81 | EGLN2 (0.44) | EGLN2ALDH1A1MAPK1KDM4ETSHR | |
| SCHEMBL3277090 | 0.81 | MAPK1 (0.39) | ALDH1A1MAPK1KDM4ETSHRALOX15 | |
| SCHEMBL23925431 | 0.79 | EGLN2 (0.57) | EGLN2 | |
| SCHEMBL14108156 | 0.78 | KDM4E (0.43) | ALDH1A1MAPK1KDM4ETSHRALOX15 | |
| SCHEMBL7493866 | 0.77 | KDM4E (0.35) | EGLN2ALDH1A1MAPK1KDM4ETSHR | |
| SCHEMBL6068253 | 0.75 | ALDH1A1 (0.32) | ALDH1A1MAPK1KDM4ETSHRALOX15 | |
| SCHEMBL6068255 | 0.75 | ALDH1A1 (0.32) | ALDH1A1MAPK1KDM4ETSHRALOX15 | |
| SCHEMBL6186514 | 0.75 | SMN1; SMN2 (0.41) | ALDH1A1MAPK1KDM4ETSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131708-A1 | Method For Production of Substituted Phenylmalonate Esters, Intermediate Compounds and The Use Thereof for production of 5, 7-dihydroxy-6-(2,4,5-trifluorophenyl)-(1,2,4)triazolo(1,5-A)pyrimidines | BASF AKTIENGESELLSCHAFT (DE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131708-A1 | Method For Production of Substituted Phenylmalonate Esters, Intermediate Compounds and The Use Thereof for production of 5, 7-dihydroxy-6-(2,4,5-trifluorophenyl)-(1,2,4)triazolo(1,5-A)pyrimidines | DHPS, PAH, HPD | EGLN2 516/4885ALDH1A1 182/4885MAPK1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.